All Stories

  1. The Australia New Zealand respiratory audit programme: a new paradigm to improve respiratory care

    Article • Internal Medicine Journal, December 2025, Wiley

    James Fingleton

  2. General practitioners’ attitudes towards liquid biopsy as a diagnostic test for advanced lung cancer

    Article • The Journal of Liquid Biopsy, December 2025, Elsevier

    James Fingleton

  3. New Zealand Chronic Obstructive Pulmonary Disease Guidelines: 2025 update

    Article • New Zealand Medical Journal, November 2025, Pasifika Medical Association

    James Fingleton

  4. Response to Biologics Along a Gradient of T2 Involvement in Patients With Severe Asthma: A Data-Driven Biomarker Clustering Approach

    Article • The Journal of Allergy and Clinical Immunology In Practice, September 2025, Elsevier

    James Fingleton

  5. Review of the New Zealand Asthma and Respiratory Foundation’s New Zealand Adolescent and Adult Asthma guidelines

    Article • New Zealand Medical Journal, June 2025, Pasifika Medical Association

    James Fingleton

  6. Treatable Trait Guided Asthma Management: A Feasibility Study

    Article • Respirology, March 2025, Wiley

    James Fingleton

  7. Environmental impact of inhaled medicines: A Thoracic Society of Australia and New Zealand position statement

    Article • Respirology, November 2024, Wiley

    James Fingleton

  8. Real‐world biologics response and super‐response in the International Severe Asthma Registry cohort

    Article • Allergy, June 2024, Wiley

    James Fingleton

  9. Evaluating the Feasibility of a Community Pharmacy-Delivered Behaviour Change Intervention to Reduce Reliever Reliance in Asthma

    Article • Patient Preference and Adherence, February 2024, Taylor & Francis

    James Fingleton

  10. Treatable trait guided asthma management: biomarker changes and responder analysis

    Article • September 2023, European Respiratory Society (ERS)

    James Fingleton

  11. Prevention of Re-Hospitalization for Acute Exacerbations: Perspectives of People with Chronic Obstructive Pulmonary Disease: A Qualitative Study

    Article • International Journal of Chronic Obstructive Pulmonary Disease, March 2023, Taylor & Francis

    James Fingleton

  12. Taking Charge After Acute Exacerbation of Chronic Obstructive Pulmonary Disease: A Randomized Controlled Feasibility Trial of a Psychologically Informed Self-Management Intervention

    Article • International Journal of Chronic Obstructive Pulmonary Disease, March 2023, Taylor & Francis

    James Fingleton

  13. A survey of adult respiratory and sleep services in Aotearoa New Zealand: inequities in the provision of adult respiratory and sleep services

    Article • New Zealand Medical Journal, December 2022, Pasifika Medical Association

    James Fingleton

  14. Metabolomic changes related to airway inflammation, asthma pathogenesis and systemic activity following inhaled fluticasone furoate/vilanterol: a randomized controlled trial

    Article • Respiratory Research, September 2022, Springer Science + Business Media

    James Fingleton

  15. Asthma control with ICS-formoterol reliever versus maintenance ICS and SABA reliever therapy: a post hoc analysis of two randomised controlled trials

    Article • BMJ Open Respiratory Research, August 2022, BMJ

    James Fingleton

  16. Rhinothermy delivered by nasal high flow therapy in the treatment of the common cold: a randomised controlled trial

    Article • BMJ Open, November 2021, BMJ

    James Fingleton

  17. Defining a Severe Asthma Super-Responder: Findings from a Delphi Process

    Article • The Journal of Allergy and Clinical Immunology In Practice, November 2021, Elsevier

    James Fingleton

  18. Epinephrine (adrenaline) compared to selective beta-2-agonist in adults or children with acute asthma: a systematic review and meta-analysis

    Article • Thorax, September 2021, BMJ

    James Fingleton

  19. Study protocol for a feasibility trial in community pharmacy of a personalised behaviour change intervention to reduce reliever reliance and overuse in individuals with asthma.

    Article • May 2021, Springer Science + Business Media

    James Fingleton

  20. Adrenaline (epinephrine) compared to selective beta-2-agonist in adults or children with acute asthma: a systematic review and meta-analysis

    Article • February 2021, Cold Spring Harbor Laboratory Press

    James Fingleton

  21. Severe asthma assessment, management and the organisation of care in Australia and New Zealand: expert forum roundtable meetings

    Article • Internal Medicine Journal, February 2021, Wiley

    James Fingleton

  22. Engaging Māori with qualitative healthcare research using an animated comic

    Article • Health Promotion International, December 2020, Oxford University Press (OUP)

    James Fingleton

  23. ICS-formoterol reliever versus ICS and short-acting β2-agonist reliever in asthma: a systematic review and meta-analysis

    Article • ERJ Open Research, October 2020, European Respiratory Society (ERS)

    Lee Hatter, James Fingleton

  24. Systematic review of the comparison between adrenaline (epinephrine) and selective ß2-agonist in the setting of adults or children with acute asthma

    Article • September 2020, European Respiratory Society (ERS)

    James Fingleton

  25. Patient preferences for asthma management: a qualitative study

    Article • September 2020, European Respiratory Society (ERS)

    James Fingleton

  26. Patient preferences for asthma management: a qualitative study

    Article • BMJ Open, August 2020, BMJ

    James Fingleton

  27. What matters most to patients when choosing treatment for mild–moderate asthma? Results from a discrete choice experiment

    Article • Thorax, July 2020, BMJ

    James Fingleton

  28. Predictive value of blood eosinophils and exhaled nitric oxide in adults with mild asthma: a prespecified subgroup analysis of an open-label, parallel-group, randomised controlled trial

    Article • The Lancet Respiratory Medicine, July 2020, Elsevier

    James Fingleton

  29. Self-titration of inhaled corticosteroid and β2-agonist in response to symptoms in mild asthma: a pre-specified analysis from the PRACTICAL randomised controlled trial

    Article • European Respiratory Journal, May 2020, European Respiratory Society (ERS)

    James Fingleton

  30. Patient preferences for symptom-driven or regular preventer treatment in mild to moderate asthma: findings from the PRACTICAL study, a randomised clinical trial

    Article • European Respiratory Journal, February 2020, European Respiratory Society (ERS)

    James Fingleton

  31. P226 Combined analysis of two randomized controlled trials of budesonide/formoterol reliever therapy in adults with mild asthma

    Article • November 2019, BMJ

    James Fingleton

  32. Pre-apneic capnography waveform abnormalities during procedural sedation and analgesia

    Article • Journal of Clinical Monitoring and Computing, September 2019, Springer Science + Business Media

    James Fingleton

  33. Late Breaking Abstract - Open-label trial of budesonide/formoterol reliever therapy in mild asthma

    Article • September 2019, European Respiratory Society (ERS)

    James Fingleton

  34. Which traits to target in asthma? Importance of treatable traits varies depending on desired outcome

    Article • September 2019, European Respiratory Society (ERS)

    James Fingleton

  35. What do patients want? Preferences for two asthma regimens in mild/moderate asthma

    Article • September 2019, European Respiratory Society (ERS)

    James Fingleton

  36. Discrete choice experiments identifying attributes influencing treatment preference in mild asthma

    Article • September 2019, European Respiratory Society (ERS)

    James Fingleton

  37. Budesonide-formoterol reliever therapy versus maintenance budesonide plus terbutaline reliever therapy in adults with mild to moderate asthma (PRACTICAL): a 52-week, open-label, multicentre, superiority, randomised controlled trial

    Article • The Lancet, September 2019, Elsevier

    James Fingleton

  38. Nasal gene expression changes with inhaled corticosteroid treatment in asthma

    Article • Allergy, July 2019, Wiley

    James Fingleton

  39. Sequence analysis of capnography waveform abnormalities during nurse-administered procedural sedation and analgesia in the cardiac catheterization laboratory

    Article • Scientific Reports, July 2019, Springer Science + Business Media

    James Fingleton

  40. Protocol for a randomised, single-blind, two-arm, parallel-group controlled trial of the efficacy of rhinothermy delivered by nasal high flow therapy in the treatment of the common cold

    Article • BMJ Open, June 2019, BMJ

    James Fingleton

  41. Controlled Trial of Budesonide–Formoterol as Needed for Mild Asthma

    Article • The New England Journal of Medicine and Surgery and the Collateral Branches of Science, May 2019, New England Journal of Medicine (NEJM/MMS)

    James Fingleton

  42. Nasal high‐flow therapy compared with non‐invasive ventilation in COPD patients with chronic respiratory failure: A randomized controlled cross‐over trial

    Article • Respirology, May 2019, Wiley

    James Fingleton

  43. Severe Asthma Global Evaluation (SAGE): An Electronic Platform for Severe Asthma

    Article • The Journal of Allergy and Clinical Immunology In Practice, May 2019, Elsevier

    James Fingleton

  44. Treatable traits: a new paradigm for 21st century management of chronic airway diseases: Treatable Traits Down Under International Workshop report

    Article • European Respiratory Journal, March 2019, European Respiratory Society (ERS)

    vanessa mcdonald, James Fingleton, Conjoint Professor Peter Wark

  45. The duration of anti-inflammatory action of fluticasone furoate (FF) assessed via exhaled nitric oxide (FeNO) in asthmatics following administration of FF/vilanterol (VI)

    Article • Pneumologie, February 2019, Thieme Publishing Group

    James Fingleton

  46. Serum periostin levels in adults of Chinese descent: an observational study

    Article • Allergy Asthma & Clinical Immunology, December 2018, Springer Science + Business Media

    James Fingleton

  47. Type 2 Biomarkers and Prediction of Future Exacerbations and Lung Function Decline in Adult Asthma

    Article • The Journal of Allergy and Clinical Immunology In Practice, November 2018, Elsevier

    James Fingleton

  48. Oxygen versus air-driven nebulisers for exacerbations of chronic obstructive pulmonary disease: a randomised controlled trial

    Article • BMC Pulmonary Medicine, October 2018, Springer Science + Business Media

    James Fingleton

  49. Late Breaking Abstract - Which treatable traits matter? Prevalence of treatable traits and risk of exacerbation in a random population sample with asthma

    Article • September 2018, European Respiratory Society (ERS)

    James Fingleton

  50. Accuracy and precision of transcutaneous carbon dioxide monitoring: a systematic review and meta-analysis

    Article • Thorax, September 2018, BMJ

    James Fingleton

  51. Serum periostin levels following small bone fractures, long bone fractures and joint replacements: an observational study

    Article • Allergy Asthma & Clinical Immunology, July 2018, Springer Science + Business Media

    James Fingleton

  52. Change in biomarkers of type-2 inflammation following severe exacerbations of asthma

    Article • Thorax, July 2018, BMJ

    James Fingleton

  53. Anti-inflammatory duration of action of fluticasone furoate/vilanterol trifenatate in asthma: a cross-over randomised controlled trial

    Article • July 2018, Springer Science + Business Media

    James Fingleton

  54. Randomised controlled trial of rhinothermy for treatment of the common cold: a feasibility study

    Article • BMJ Open, March 2018, BMJ

    James Fingleton

  55. The inhaled corticosteroid/long-acting β-agonist maintenance and reliever therapy regimen: where to from here?

    Article • European Respiratory Journal, January 2018, European Respiratory Society (ERS)

    James Fingleton, James Harper

  56. Treatable traits of chronic airways disease

    Article • Current Opinion in Pulmonary Medicine, January 2018, Wolters Kluwer Health

    James Fingleton

  57. Phenotypes of symptomatic airways disease in China and New Zealand

    Article • European Respiratory Journal, December 2017, European Respiratory Society (ERS)

    James Fingleton

  58. Nasal high flow therapy and PtCO2 in stable COPD: A randomized controlled cross-over trial

    Article • Respirology, September 2017, Wiley

    Dr Irene E Braithwaite, James Fingleton, James Harper

  59. Late Breaking Abstract - The duration of anti-inflammatory action of fluticasone furoate (FF) assessed via exhaled nitric oxide (FeNO) in asthmatics following administration of FF/vilanterol (VI)

    Article • September 2017, European Respiratory Society (ERS)

    James Fingleton

  60. Oxygen compared to air driven nebulisers for acute exacerbations of COPD: a randomised controlled trial

    Article • September 2017, European Respiratory Society (ERS)

    James Fingleton

  61. Description of the protocol for the PRACTICAL study: a randomised controlled trial of the efficacy and safety of ICS/LABA reliever therapy in asthma

    Article • BMJ Open Respiratory Research, July 2017, BMJ

    James Fingleton

  62. Longitudinal variation of serum periostin levels in adults with stable asthma

    Article • Journal of Allergy and Clinical Immunology, May 2017, Elsevier

    James Fingleton

  63. RCT of the effect of berryfruit polyphenolic cultivar extract in mild steroid-naive asthma: a cross-over, placebo-controlled study

    Article • BMJ Open, March 2017, BMJ

    James Fingleton

  64. Day-time variation of serum periostin in asthmatic adults treated with ICS/LABA and adults without asthma

    Article • Allergy Asthma & Clinical Immunology, February 2017, Springer Science + Business Media

    James Fingleton

  65. Reference ranges for serum periostin in a population without asthma or chronic obstructive pulmonary disease

    Article • Clinical & Experimental Allergy, June 2016, Wiley

    James Fingleton, James Harper

  66. Serum periostin in obstructive airways disease

    Article • European Respiratory Journal, February 2016, European Respiratory Society (ERS)

    James Fingleton

  67. Randomised controlled trial of topical kanuka honey for the treatment of acne

    Article • BMJ Open, January 2016, BMJ

    James Fingleton

  68. Treatment responsiveness of phenotypes of symptomatic airways obstruction in adults

    Article • Journal of Allergy and Clinical Immunology, September 2015, Elsevier

    James Fingleton

  69. A single-blind randomised controlled trial of topical kanuka honey for the treatment of nappy rash

    Article • Focus on Alternative and Complementary Therapies, August 2015, Wiley

    James Fingleton

  70. Randomised controlled trial of topical kanuka honey for the treatment of rosacea

    Article • BMJ Open, June 2015, BMJ

    James Fingleton

  71. Randomised controlled trial of topical kanuka honey for the treatment of cold sores

    Article • Advances in Integrative Medicine, December 2014, Elsevier

    James Fingleton

  72. S43 Real World Experience Of The Use Of Pet-ct For Distinguishing Between Benign Pleural Disease And Malignant Mesothelioma

    Article • Thorax, November 2014, BMJ

    James Fingleton

  73. A randomised controlled trial of topical Kanuka honey for the treatment of psoriasis

    Article • JRSM Open, March 2014, SAGE Publications

    James Fingleton

  74. A randomised controlled trial of topical Kanuka honey for the treatment of eczema

    Article • JRSM Open, January 2014, SAGE Publications

    James Fingleton

  75. Topical kanuka honey for the treatment of nappy rash

    Article • Focus on Alternative and Complementary Therapies, January 2014, Wiley

    James Fingleton

  76. Letter in response to Tashkinet al: limited generalisability of uplift findings to clinical practice

    Article • Thorax, November 2013, BMJ

    James Fingleton

  77. Topical kanuka honey for the treatment of rosacea

    Article • Focus on Alternative and Complementary Therapies, September 2013, Wiley

    James Fingleton

  78. Limited generalisability of UPLIFT findings to clinical practice: Table 1

    Article • Thorax, June 2013, BMJ

    James Fingleton

  79. Efficacy of Micromobile Foot Compression Device in Increasing Lower Limb Venous Blood Flow

    Article • International Journal of Vascular Medicine, January 2013, Hindawi Publishing Corporation

    James Fingleton

  80. A half doubling dose change in bronchial hyperresponsiveness in a population represents an important difference

    Article • Translational Respiratory Medicine, January 2013, Springer Science + Business Media

    James Fingleton

  81. Restriction of LABA use to combination ICS/LABA inhaler therapy in asthma

    Article • Thorax, November 2012, BMJ

    James Fingleton

  82. Bronchodilator responsiveness: interpret with caution

    Article • Thorax, June 2012, BMJ

    James Fingleton

  83. Proposed MHRA changes to UK children's paracetamol dosing recommendations: modelling study

    Article • Journal of the Royal Society of Medicine, May 2012, SAGE Publications

    James Fingleton

  84. Towards individualised medicine for airways disease: identifying clinical phenotype groups: Figure 1–

    Article • European Respiratory Journal, March 2012, European Respiratory Society (ERS)

    James Fingleton

  85. Individualized treatment for asthma

    Article • January 2012, Future Medicine

    James Fingleton

  86. British National Formulary for Children: the risk of inappropriate paracetamol prescribing

    Article • Archives of Disease in Childhood, October 2011, BMJ

    James Fingleton

  87. Towards individualised treatment in COPD

    Article • Thorax, January 2011, BMJ

    James Fingleton